Nyrada Inc -Statistically Significant Neuroprotection Achieved in Nyrada’s Preclinical Brain Injury Study

Highlights:
•Nyrada’s lead Brain Injury Program drug candidate NYR-BI03 demonstrated strong efficacy in reducing injury in a preclinical study.
•NYR-BI03 is a first-in-class therapy with a novel mechanism of action targeting significant market opportunity.
•Supporting NYR-BI03’s favourable safety profile, the current study had no drug-related adverse effects.
•Good Laboratory Practice (GLP) safety testing to commence this current quarter.
•Walter Reed Army Institute of Research (US Military) brain injury study to commence this current quarter.
•Phase I clinical trial scheduled for the second half of the 2024 calendar year.